Diabetes drugs from Eli Lilly and Novo Nordisk, such as Mounjaro, Zepbound, Ozempic, and Wegovy, are expanding beyond ...

The pharma giant cut its guidance and named a new CEO, hoping to revive growth. Its stock fell as much as 30%, wiping almost $93 billion from its market value.

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk stock took a big hit early Tuesday after the Danish weight-loss drugmaker unexpectedly cut its full-year guidance for the U.S.It also announced a new CEO, appointing an insider to lead ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.